Two imidazoquinoxaline ligands for the benzodiazepine site sharing a second low affinity site on rat GABAA receptors but with the opposite functionality

Imidazoquinoxaline PNU‐97775 and imidazoquinoline PNU‐101017 are benzodiazepine site ligands with a second low affinity binding site on GABAA receptors, the occupancy of which at high drug concentrations reverses their positive allosteric activity via the benzodiazepine site, and may potentially min...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of pharmacology Vol. 123; no. 8; pp. 1490 - 1494
Main Authors Im, Haesook K., Bin Im, Wha, Pregenzer, Jeffrey F., Stratman, Nancy C., VonVoigtlander, Philip F., Jon Jacobsen, E.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.04.1998
Nature Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Imidazoquinoxaline PNU‐97775 and imidazoquinoline PNU‐101017 are benzodiazepine site ligands with a second low affinity binding site on GABAA receptors, the occupancy of which at high drug concentrations reverses their positive allosteric activity via the benzodiazepine site, and may potentially minimize abuse liability and physical dependence. In this study we discovered, with two imidazoquinoxaline analogues, that the functionality of the second site was altered by the nitrogen substituent on the piperazine ring moiety: PNU‐100076 with a hydrogen substituent on the position produced a negative allosteric effect via the second low affinity site, like the parent compounds, while PNU‐100079 with a trifluoroethyl substituent produced a positive allosteric response. These functional characteristics were monitored with Cl− currents measurements in cloned rat αxβ2γ2 subtypes of GABAA receptors expressed in human embryonic kidney 293 cells, and further confirmed in rat cerebrocortical membranes containing complex subtypes of GABAA receptors with binding of [35S]‐TBPS, which is a high affinity ligand specific for GABAA receptors with exquisite sensitivity to allosteric modulations. This structure‐functional relationship could be exploited to further our understanding of the second allosteric site of imidazoquinoxaline analogues, and to develop more effective benzodiazepine site ligands without typical side effects associated with those currently available on the market. British Journal of Pharmacology (1998) 123, 1490–1494; doi:10.1038/sj.bjp.0701763
ISSN:0007-1188
1476-5381
DOI:10.1038/sj.bjp.0701763